03.

Investors

Here you will find financial calendar, reports, information about the share and corporate governance

Change of Trading place 2020

Financial calendar

Q1 report, 2020
31 January, 2020
Q2 report, 2020
29 April, 2020
Q3 report, 2020
31 July, 2020
Year End Report 2020
30 October, 2020
Annual General Meeting
December, 2020

Financial reports

2020

2019

2018

2017

2016

2015

Corporate Governance

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as per 2020-03-31:‍

Owner
Shares
Percentage
Diamyd Medical AB
2,453,485
12.82
Avanza Pension*
2,373,525
12.40
Anders Essen-Möller
911,721
4.76
Robert Joki
657,970
3.44
Polski Bank Komorek Macierzystych
602,483
3.15
Bertil Lindqvist
574,323
3.00
Pabros AB (previously MabTech Group AB)
485,360
2.54
Nordnet Pensionsförsäkring AB
439,162
2.29
BioAll AB**
360,578
1.88
Konstruktions och försäljningsaktiebolaget
2,453,485
1.85
Total
8,653,590
45.20
*Chairman Anders Essen-Möller holds shares corresponding to 4.98 percent (558,885 shares) of votes and capital in NextCell which is managed through Avanza Pension. This is in addition to his directly registered share holdings.

** CEO Mathias Svahn holds both directly registered shares and shares via his company BioAll AB. In this overview the holdings are combined.

Trading information

NextCell Pharma AB is listed on the Spotlight Stock Market since July 2017. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Spotlight Stock Markets website:

Spotlight Stock Market

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.

Archived documents